Neoral and Viberzi

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

CycloSPORINE may significantly increase the blood levels of eluxadoline. This may increase the risk and/or severity of side effects such as drowsiness, nausea, vomiting, constipation, abdominal pain, and rarely, pancreatitis (inflammation of the pancreas). Talk to your doctor if you have any questions or concerns. Your doctor may already be aware of the interaction, but has determined that this is the best course of treatment for you and has taken appropriate precautions and is monitoring you closely for any potential complications. You should seek immediate medical attention if you experience potential symptoms of pancreatitis such as persistent nausea, vomiting, abdominal tenderness, and upper abdominal pain, especially that which is made worse after eating or radiates to the back or shoulders. Symptoms of pancreatitis usually go away when treatment with eluxadoline is stopped. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

ADJUST DOSE: Coadministration with inhibitors of organic anion transporting polypeptide (OATP) 1B1 may significantly increase the plasma concentrations of eluxadoline. Based on available data, inhibition of OATP1B1-mediated hepatic uptake appears to reduce both the hepatic first-pass extraction and systemic biliary clearance of eluxadoline. In 30 healthy volunteers, administration of a single 100 mg dose of eluxadoline with a single 600 mg dose of cyclosporine, a known OATP1B1 inhibitor, increased eluxadoline peak plasma concentration (Cmax) and systemic exposure (AUC) by 6.2- and 4.4-fold, respectively, compared to administration of eluxadoline alone. Adverse events were reported in 6 study subjects during coadministration of eluxadoline with cyclosporine and in 2 subjects during administration of eluxadoline alone.

MANAGEMENT: The recommended dosage of eluxadoline is 75 mg twice daily when used with OATP1B1 inhibitors. Patients should be monitored for adverse effects such as sedation, nausea, vomiting, constipation, abdominal pain, liver enzyme elevations, and pancreatitis.

Neoral

Generic Name: cyclosporine

Brand name: Gengraf, Neoral, Sandimmune, Sandimmune

Synonyms: Neoral (Capsules, Modified)

What is Neoral?

Viberzi

Generic Name: eluxadoline

Brand name: Viberzi

Synonyms: n.a.

What is Viberzi?